Neurology
RSSArticles
-
Secukinumab Injection (Cosentyx™)
A recombinant, fully humanized monoclonal antibody to interleukin-17 has been approved for the treatment of moderate-to-severe plaque psoriasis. Secukinumab is marketed by Novartis as Cosentyx.
-
B-type Natriuretic Peptides (BNP) Values Improve CVD Risk Prediction
Elevated BNP values in a large cohort of women with numerous CV events modestly improved measures of CVD risk prediction.
-
Does a Link Exist Between OSA and CAD?
Obstructive sleep apnea is associated with coronary artery calcification in non-obese individuals, but the effect is largely attenuated by body mass index.
-
Statins After an MI: Does it Happen?
Following hospital discharge for a heart attack, the majority of Medicare patients do not get recommended high-intensity statin therapy.
-
Clinical Briefs
Ambulatory BP Monitoring, A New Oral Treatment for Hyperkalemia: Patiromer, Obesity Leads to Overdiagnosis of Airflow Obstruction
-
Strengthen the Feet to Treat Plantar Fasciitis
SYNOPSIS: A strength training exercise improved self-reported 3-month outcomes in treating plantar fasciitis compared with inserts and stretching.
-
Effects of Coenzyme Q10 in Chronic Heart Failure Patients
SYNOPSIS: Treatment with coenzyme Q10 in addition to standard therapy for patients with moderate to severe HF is safe, well tolerated, and associated with a reduction in symptoms and major adverse cardiovascular events.
-
Is BMI Good Enough to Measure Visceral Adiposity?
SYNOPSIS: A large international study found frequent discordance between body mass index (BMI) and waist circumference (WC), driven by the substantial variability in visceral adiposity. Within each BMI category, patients with the highest WC were more likely to have higher cardiometabolic risk.
-
Alternating Morphology Every-other-beat
Interpretation: The underlying rhythm in this simultaneously recorded 3-lead tracing is a narrow-complex tachycardia.
-
Peramivir: A Newly Approved Antiviral for Treatment of Influenza
Peramivir (Rapivab™) was recently approved by the FDA in December 2014 for treatment of acute uncomplicated influenza within two days of symptom onset. This newly approved antiviral is a neuraminidase inhibitor (NI) similar to oseltamivir and zanamivir but the first to be approved in an injectable formulation.1 Peramivir has been licensed in Japan (as Rapiacta) and South Korea (as PeramiFlu) since 2010. In addition, it has been used in the United States on an emergency basis during the 2009 H1N1 flu pandemic.